Mapmygenome Acquires dnaPower Inc. to Expand North American Presence

VANCOUVER, BC, Oct. 21, 2026 /CourierPR/ -- Mapmygenome has completed the acquisition of Vancouver-based dnaPower Inc., a pioneer in personal genomics, significantly expanding its North American presence and establishing a market-leading platform in DNA, microbiome, longevity, and precision health testing.

Founded in 2008, dnaPower has been a key player in the personal genomics space, offering actionable DNA-based health, nutrition, fitness, methylation, and longevity insights for consumers and practitioners. By integrating dnaPower with its global scale and premier CAP-accredited clinical laboratory capabilities, including the Vancouver-based Microbiome Insights, acquired in 2025, Mapmygenome aims to define the next frontier in microbiome, longevity, and precision health testing.

The strategic transaction integrates dnaPower's consumer reach with Mapmygenome's global footprint, technology stack, and research and development pipeline. This combination will enable the creation of a centralized platform for DNA, microbiome, pharmacogenetic, and longevity testing, dedicated to proactive, preventive healthcare across Canada and the United States.

Strategic Highlights: - Market Expansion: Integrates dnaPower's consumer reach with Mapmygenome's global footprint, technology stack, and R&D pipeline. - Integrated Longevity Engine: Combines multi-omics analytics and clinical laboratory capabilities to deploy new commercial offerings in healthy aging, gut profiling, and epigenetic assessment. - Centralized Operations: Establishes a Vancouver processing hub operating under CAP-accredited and ISO-certified protocols.

Comprehensive Testing Suite: - Longevity and Gut Health: Advanced shotgun metagenomic sequencing, gut microbiome profiling, epigenetic biological age panels, and longevity insights. - Genomic and Preventive Health: Whole-genome and exome sequencing, pharmacogenetics, DNA wellness panels, methylation testing, and clinical bioinformatics.

Mapmygenome, a global leader in personal genomics, longevity solutions, and precision medicine, now combines AI-driven multi-omics with premier CAP-accredited clinical laboratory infrastructure to empower individuals and healthcare providers with actionable insights across whole-genome sequencing, gut health, and healthy aging.